Signal transducer and activator of transcription 3 is a major kinase-independent _target of sorafenib in hepatocellular carcinoma
- PMID: 21354226
- DOI: 10.1016/j.jhep.2011.01.047
Signal transducer and activator of transcription 3 is a major kinase-independent _target of sorafenib in hepatocellular carcinoma
Erratum in
-
Corrigendum to "Signal transducer and activator of transcription 3 is a major kinase-independent _target of sorafenib in hepatocellular carcinoma".J Hepatol. 2017 Mar;66(3):666-668. doi: 10.1016/j.jhep.2016.12.007. Epub 2017 Jan 6. J Hepatol. 2017. PMID: 28069352 No abstract available.
Abstract
Background & aims: Recently, we reported that sorafenib sensitizes hepatocellular carcinoma (HCC) cells to TRAIL through the inhibition of signal transducer and activator of transcription 3 (STAT3). Here, we report that sorafenib inhibits HCC via a kinase-independent mechanism: SHP-1 dependent STAT3 inactivation.
Methods: SC-1 is a sorafenib derivative that closely resembles sorafenib structurally but with no kinase inhibition activity. HCC cell lines (PLC5, Huh-7, Hep3B, and Sk-Hep1) were treated with sorafenib or SC-1 and apoptosis and signal transduction were analyzed. In vivo efficacy was determined in nude mice with Huh-7 xenografts.
Results: SC-1 showed similar effects to sorafenib on growth inhibition and apoptosis in all tested HCC cell lines. SC-1 down-regulated phosphorylation of phospho-STAT3 (p-STAT3) at tyrosine 705 in all tested HCC cells. Expression of STAT3-driven genes, including Cyclin D1 and Survivin, was also repressed by SC-1. Luciferase reporter assay confirmed the inhibition of transcriptional activity of STAT3 in both sorafenib-treated and SC-1-treated cells. Ectopic expression of STAT3 in PLC5 cells abolished apoptosis in SC-1-treated cells. Sorafenib and SC-1 up-regulated SHP-1 activity. Knockdown of SHP-1, but not SHP-2 or PTP-1B, by small interference RNA reduced apoptosis induced by SC-1. Finally, SC-1 reduced Huh-7 tumor growth significantly in vivo, which was associated with down-regulation of p-STAT3 and up-regulation of SHP-1 activity.
Conclusions: STAT3 is a major kinase-independent _target of sorafenib in HCC.
Copyright © 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Comment in
-
_targeting STAT3 in hepatocellular carcinoma: sorafenib again….J Hepatol. 2011 Nov;55(5):957-9. doi: 10.1016/j.jhep.2011.06.005. Epub 2011 Jun 28. J Hepatol. 2011. PMID: 21718664 No abstract available.
Similar articles
-
Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.Mol Cancer Ther. 2012 Feb;11(2):452-63. doi: 10.1158/1535-7163.MCT-11-0412. Epub 2011 Dec 16. Mol Cancer Ther. 2012. PMID: 22180308
-
Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer.J Thorac Oncol. 2014 Apr;9(4):488-96. doi: 10.1097/JTO.0000000000000107. J Thorac Oncol. 2014. PMID: 24736071
-
A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.Cancer Lett. 2014 Jul 28;349(2):136-43. doi: 10.1016/j.canlet.2014.04.006. Epub 2014 Apr 13. Cancer Lett. 2014. PMID: 24735751
-
Downregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy.World J Gastroenterol. 2014 Nov 7;20(41):15269-74. doi: 10.3748/wjg.v20.i41.15269. World J Gastroenterol. 2014. PMID: 25386075 Free PMC article. Review.
-
PDGFRalpha: a new therapeutic _target in the treatment of hepatocellular carcinoma?Expert Opin Ther _targets. 2009 Apr;13(4):443-54. doi: 10.1517/14728220902719233. Expert Opin Ther _targets. 2009. PMID: 19335066 Review.
Cited by
-
NUPR1, a new _target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance.Cell Death Dis. 2016 Jun 23;7(6):e2269. doi: 10.1038/cddis.2016.175. Cell Death Dis. 2016. PMID: 27336713 Free PMC article.
-
Current systemic treatment of hepatocellular carcinoma: A review of the literature.World J Hepatol. 2015 Jun 8;7(10):1412-20. doi: 10.4254/wjh.v7.i10.1412. World J Hepatol. 2015. PMID: 26052386 Free PMC article. Review.
-
Comparative Analysis of the Cytotoxic Effect of a Complex of Selenium Nanoparticles Doped with Sorafenib, "Naked" Selenium Nanoparticles, and Sorafenib on Human Hepatocyte Carcinoma HepG2 Cells.Int J Mol Sci. 2022 Jun 14;23(12):6641. doi: 10.3390/ijms23126641. Int J Mol Sci. 2022. PMID: 35743086 Free PMC article.
-
Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells.Mol Oncol. 2017 Mar;11(3):266-279. doi: 10.1002/1878-0261.12033. Epub 2017 Feb 7. Mol Oncol. 2017. PMID: 28084011 Free PMC article.
-
Treatment of Liver Cancer.Cold Spring Harb Perspect Med. 2015 Jul 17;5(9):a021535. doi: 10.1101/cshperspect.a021535. Cold Spring Harb Perspect Med. 2015. PMID: 26187874 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous